Last updated: February 24, 2026
What is the Drug?
NDC 00113-0428 corresponds to Trametinib (brand name Mekinist), a targeted therapy used primarily for BRAF V600E or V600K mutation-positive melanoma. It is a MEK inhibitor approved by the FDA since 2013.
Current Market Landscape
Market Size
- Estimated global melanoma treatment market: $500 million in 2022, projected to grow at approximately 8% annually through 2027.
- US melanoma indications: Approximately 7,000 new cases annually, with about 35% harboring BRAF V600 mutations.
- Patient volume: About 2,450 patients eligible for trametinib therapy annually in the US; similar trends in Western Europe.
Competition
- Key competitors include Dabrafenib + Trametinib combo (Novartis), Encorafenib + Binimetinib (Array BioPharma/Bayer), and Vemurafenib.
- Monotherapy options are declining due to combination therapies offering better efficacy and safety profiles.
- Patent expirations for some competitors approaching in 2025–2027, potentially affecting market share.
Regulatory Status and Approvals
- Approved for metastatic or unresectable melanoma with BRAF V600 mutations, either as monotherapy or part of combination regimens.
- FDA-approved in 2013; EMA approved in 2014.
- Expanding indications include adjuvant therapy for resected melanoma with BRAF mutations (pending or approved in some markets).
Key Drivers
- Rising melanoma incidence.
- Increased testing for BRAF mutations.
- Favorable outcomes with combination therapies increasing overall treatment prevalence.
- Growing adoption of targeted therapies over traditional chemotherapy.
Price Benchmarks and Historical Trends
Benchmark Pricing
| Region |
Wholesale Acquisition Cost (WAC) per 30-day supply |
Notes |
| US |
$13,000 – $15,000 |
Approximate, varies by pharmacy and payer negotiations |
| EU |
€9,000 – €11,000 |
Varies across countries; some countries have negotiated prices |
| Canada |
CAD 16,000 – CAD 18,000 |
Price includes dispensing fees |
Price Trends
- Prices steady since FDA approval, with marginal reductions in negotiations.
- No significant price erosion observed yet.
- Price increases were recorded during initial launch phases, typically about 3–5% annually across regions.
Reimbursement and Payer Coverage
- High coverage in US commercial plans and Medicare.
- Prior authorization common due to high costs.
- Cost-effectiveness analyses favor combination therapies, though monotherapy remains a standard treatment.
Price Projections (Next 3–5 Years)
| Scenario |
Monotherapy Price Trend |
Factors Considered |
| Conservative |
Stability at ~$14,000 per 30-day supply |
Existing patents prevent significant discounts; payer negotiations unlikely to reduce list prices substantially. |
| Moderate |
Slight decline of 3–5% annually |
Increased competition from biosimilars or newer agents, potential policy pressures on drug prices. |
| Aggressive |
10%+ reduction within 2 years |
Major policy reforms, patent litigation or biosimilar entry, or legal challenges may accelerate price erosion. |
Key Influences
- Patent Lifecycle: Original patents expire in 2028, but data exclusivity may extend profits until then.
- Market Penetration: Growing use in adjuvant settings could expand volume but pressure prices downward.
- Cost-Effectiveness: Health technology assessments in key markets could influence negotiated prices.
Future Market Opportunities
- New indications: Trials for combining trametinib with immunotherapies or in non-melanoma BRAF-mutant cancers.
- Biosimilars and Generics: Not applicable currently; patent expiration could change this landscape by 2028.
- Combination Regimens: Markets shifting towards fixed-dose combinations with BRAF inhibitors, impacting monotherapy sales.
Risks and Challenges
- Pricing pressures: Payer pushback on high drug costs.
- Regulatory hurdles: New indications require evidence and potential reimbursement delays.
- Market saturation: Increased competition could dampen sales growth.
Key Takeaways
- NDC 00113-0428 (trametinib) remains a significant player in melanoma therapy, with stable pricing and a growing market.
- US prices hover around $13,000–$15,000 per month; European prices range €9,000–€11,000.
- Market growth driven by increased melanoma incidence, FDA approvals, and expanded indications.
- Price projections show stability with potential minor declines due to patent expirations and competitive pressures.
- Ongoing clinical development and policy changes will influence future market dynamics.
FAQs
1. How does trametinib compare to combination therapies?
Combination regimens with BRAF inhibitors tend to have higher efficacy, leading to an increased shift from monotherapy toward combination use, impacting overall sales.
2. Are biosimilars or generics expected for trametinib?
No, patent expiry around 2028 would be the earliest opportunity for biosimilars; current exclusivity prevents generic entry.
3. What are the main regulatory hurdles for expanding trametinib’s indications?
Clinical trial data viability, demonstrating superior efficacy or safety, and reimbursement negotiations pose primary hurdles.
4. How do payer policies impact trametinib’s pricing?
Coverage is generally comprehensive, but high cost incentivizes negotiations, prior authorizations, and formulary placement decisions.
5. What emerging competitors threaten trametinib’s market share?
New MEK inhibitors and combination therapies in clinical trials could significantly impact trametinib's market share post-2025.
References
[1] IQVIA. (2022). Global Oncology Market Reports.
[2] FDA. (2013). FDA Approval of Trametinib.
[3] MarketResearch.com. (2022). Melanoma Treatment Market Size and Forecasts.
[4] National Cancer Institute. (2022). Melanoma Statistics.
[5] European Medicines Agency. (2014). EMA Approval Documents for Trametinib.
